American Society of Hematology

SHERPA: Blue

People

  1. Giralt
    Giralt
  2. Zelenetz
    Zelenetz
  3. Levine
    Levine
  4. Perales
    Perales
  5. Tallman
    Tallman
  6. O'Reilly
    O'Reilly
  7. Horwitz
    Horwitz
  8. Devlin
    Devlin
  9. Palomba
    Palomba
  10. Abdel-Wahab
    Abdel-Wahab

Groups

  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)
  7. Bone Marrow Transplant (988)
  8. Center for Molecular Imaging and Biotechnology (CMIB) (955)
  9. Lymphoma (941)
  10. Tow Center for Developmental Oncology (TCDO) (882)
Search Within
Formats
  1. Meeting Abstract (4150)
  2. Journal Article (1257)
  3. Research Letter (46)
  4. Review (44)
  5. Editorial (35)
  6. Guidelines (13)
  7. Correspondence (7)
  8. Miscellaneous (3)
Groups
  1. Department of Medicine (4000)
  2. Hematologic Malignancies, Division of (3803)
  3. Center for Hematologic Malignancies (3680)
  4. GSK Faculty (1590)
  5. Adult Leukemia (1343)
  6. Sloan Kettering Institute Faculty (1075)

More Groups

People
  1. Sergio Giralt (348)
  2. Andrew Zelenetz (341)
  3. Ross Levine (316)
  4. Miguel-Angel Perales (312)
  5. Martin Tallman (301)
  6. Richard O'Reilly (281)

More People

Years
  1. 2025 (64)
  2. 2024 (428)
  3. 2023 (478)
  4. 2022 (369)
  5. 2021 (284)
  6. 2020 (261)

More Years

Publications
  1. Blood (5174)
  2. Blood Advances (331)
  3. Hematology-American Society of Hematology Education Program (50)

Results (5555)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Nivolumab-AVD is better tolerated and improves progression-free survival compared to Bv-AVD in older patients (aged ≥60 years) with advanced stage Hodgkin lymphoma enrolled on SWOG S1826
    Meeting Abstract

    Rutherford, S. C.; Li, H.; Herrera, A. F.; Leblanc, M.; Ahmed, S.; Davison, K. L.; Casulo, C.; Bartlett, N. L.; Tuscano, J. M.; Hess, B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • With up to 8 years of therapy, asciminib (ASC) monotherapy demonstrated continued favorable efficacy, safety, and tolerability in patients (pts) with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) without the T315I mutation: Final results from the phase 1 x2101 study
    Meeting Abstract

    Hochhaus, A.; Kim, D. W.; Cortes, J.; Sasaki, K.; Mauro, M.; Hughes, T. P.; Breccia, M.; Talpaz, M.; Minami, H.; Goh, Y. T.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Glofitamab monotherapy in relapsed or refractory large B-cell lymphoma: Extended follow-up from a pivotal phase II study and subgroup analyses in patients with prior chimeric antigen receptor T-cell therapy and by baseline total metabolic tumor volume
    Meeting Abstract

    Hutchings, M.; Carlo-Stella, C.; Morschhauser, F.; Falchi, L.; Bachy, E.; Cartron, G.; Khan, C.; Tani, M.; Martinez-Lopez, J.; Bartlett, N. L.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Patient-reported outcomes of BMT CTN 1703: A randomized phase III study for GVHD prophylaxis - A quality of life evaluation
    Meeting Abstract

    Holtan, S. G.; Martens, M. J.; Al Malki, M. M.; Efebera, Y.; Kitko, C. L.; Reshef, R.; Rezvani, A. R.; Shaffer, B. C.; Solh, M. M.; Yao, J. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • (131)I-apamistamab effectively achieved durable responses in patients with R/R AML irrespective of the presence of multiple high-risk factors
    Meeting Abstract

    Seropian, S.; Foran, J. M.; Gyurkocza, B.; Nath, R.; Choe, H.; Litzow, M. R.; Koshy, N.; Stiff, P. J.; Tomlinson, B. K.; Abhyankar, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Large-scale post-transplant TCR deep sequencing reveals a major T cell diversity bottleneck with post-transplant cyclophosphamide with implications for both efficacy and toxicity: Results of the BMT CTN 1801 study
    Meeting Abstract

    Kean, L.; Siegel, S. J.; Schmalz, J. T.; Bien, S. A.; Scheffey, D.; Sanders, C.; Robins, H.; Applegate, K.; Bar, M.; Chhabra, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Allogeneic stem cell transplant and CD30 directed CART cell therapies are associated with improved survival in classical Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: Real world analysis from 14 US academic centers
    Meeting Abstract

    Voorhees, T.; Grover, N. S.; McLaughlin, E.; Florindez, J. A.; Moyo, T. K.; Reves, H.; Sumransub, N.; Deshpande, S.; Rose, A.; Duarte, C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Multicenter study of mantle cell lymphoma outcomes following first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapy
    Meeting Abstract

    Wang, Y.; Larson, M. C.; Hwang, S. R.; Kumar, A.; Joseph, A.; Hill, B. T.; Brooks, T. R.; Bond, D. A.; Maddocks, K. J.; Danilov, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Predictors of cytokine release syndrome and neurotoxicity in patients with large B-cell lymphoma and their impact on survival
    Meeting Abstract

    Shouval, R.; Strouse, C.; Kim, S.; Oloyede, T.; Ahmed, S.; Awan, F. T.; Bachanova, V.; Badar, T.; Barba, P.; Beitinjaneh, A. M.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-world evidence in the United States (US) of the impact of bridging therapy prior to axicabtagene ciloleucel (axi-cel) for the treatment of relapsed or refractory large B-cell lymphoma (R/R LBCL)
    Meeting Abstract

    Cook, M. R.; Shouval, R.; Perales, M. A.; Bezerra, E.; Niu, A.; Dahiya, S.; Nastoupil, L. J.; Jacobson, C. A.; Budde, L. E.; Olson, A. L.; more...
    Blood (2023)

    Fulltext@MSK | Save